Barclays analyst Matt Miksic lowered the firm’s price target on Zimmer Biomet (ZBH) to $94 from $100 and keeps an Underweight rating on the shares. The firm says the company’s modest Q1 beat proved “no match for a risk-off Tuesday.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet Earnings Call: Tech Momentum, Higher Guidance
- Analyst Maintains Buy on Zimmer Biomet, Keeps $109 Price Target Amid Ongoing Multi-Year Transformation
- Zimmer Biomet: Earnings Beat Masks Slowing Growth and Leadership Uncertainty, Supporting Hold Rating
- Morning Movers: Coca-Cola and Centene higher after earnings
- Zimmer Biomet Announces CFO Departure and Interim Successor